Search Results - "Jeswani, Rohini"

A Phase 1, Randomized, Double-Blind, Placebo-Controlled Single and MultipleAscending Dose Study of AMG 133 in Subjects with Obesity: Late Breaking: A Phase 1 Study of AMG 133 in Subjects with Obesity by Strande, Jennifer L., Kurra, Vamsi, Jeswani, Rohini, Oberoi, Rajneet, Sharpsten, Lucie, Neutel, Joel, Véniant, Murielle M., Parnes, Jane R.

Get full text

A Phase 1, Randomized, Double-Blind, Placebo-Controlled Single and MultipleAscending Dose Study of AMG 133 in Subjects with Obesity by Strande, Jennifer L., Kurra, Vamsi, Jeswani, Rohini, Oberoi, Rajneet, Sharpsten, Lucie, Neutel, Joel, Véniant, Murielle M., Parnes, Jane R.

Get full text

Evaluation of vascular risk in patients with migraine with and without aura treated with erenumab: Post hoc analysis of pooled long‐term clinical trial data by Kudrow, David, Dafer, Rima, Dodick, David W., Starling, Amaal, Ailani, Jessica, Dougherty, Carrie, Kalidas, Kavita, Zhang, Feng, Jeswani, Rohini, Patel, Nishil, Khodavirdi, Ani C.

“…Objective To assess cardiovascular (CV) safety of erenumab in clinical trial patients associated with degree of CV risk. Background Hypertension has been…”
Get full text

A GIPR antagonist conjugated to GLP-1 analogues promotes weight loss with improved metabolic parameters in preclinical and phase 1 settings by Véniant, Murielle M., Lu, Shu-Chen, Atangan, Larissa, Komorowski, Renee, Stanislaus, Shanaka, Cheng, Yuan, Wu, Bin, Falsey, James R., Hager, Todd, Thomas, Veena A., Ambhaikar, Malhar, Sharpsten, Lucie, Zhu, Yineng, Kurra, Vamsi, Jeswani, Rohini, Oberoi, Rajneet K., Parnes, Jane R., Honarpour, Narimon, Neutel, Joel, Strande, Jennifer L.

“…Obesity is a major public health crisis. Multi-specific peptides have emerged as promising therapeutic strategies for clinical weight loss. Glucagon-like…”
Get full text